JTE 607

Drug Profile

JTE 607

Latest Information Update: 15 Dec 2005

Price : $50

At a glance

  • Originator Japan Tobacco
  • Class Anti-inflammatories; Piperazines; Small molecules
  • Mechanism of Action Cytokine inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Systemic inflammatory response syndrome

Most Recent Events

  • 01 Nov 2005 Discontinued - Phase-I for Systemic inflammatory response syndrome (Injection)
  • 01 Nov 2005 Discontinued - Phase-II for Systemic inflammatory response syndrome in Japan (Injection)
  • 30 Oct 2003 Phase-I clinical trials in Systemic inflammatory response syndrome (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top